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Evaluating Clinical Effectiveness and Long-term Safety in
Patients with Moderate-to-Severe Asthma (EXCELS) assessed
the long-term safety of omalizumab in a clinical practice setting
as part of a phase IV US Food and Drug Administration
postmarketing commitment.
Objective: We sought to evaluate long-term safety in
omalizumab-treated and nonomalizumab-treated patients.
Primary outcome measures focused on assessment of
malignancies.
Methods: EXCELS was a prospective observational cohort
study in patients (>_12 years of age) with moderate-to-severe
allergic asthma. There were 2 cohorts: omalizumab (taking
omalizumab at baseline) and nonomalizumab (no history of
omalizumab treatment). Primary outcomes included all
confirmed, incident, study-emergent primary malignancies
(malignancies), including and excluding nonmelanoma skin
cancer (NMSC); all malignancies were externally adjudicated.
Results: The omalizumab cohort had a higher proportion of
patients with severe asthma compared with the nonomalizumab
cohort (50.0% vs 23.0%). Median follow-up was approximately
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560in the omalizumab and nonomalizumab cohorts, with a rate
ratio of 0.84 (95% CI, 0.62-1.13) for all malignancies and 0.98
(95% CI, 0.71-1.36) for all malignancies excluding NMSC.
Kaplan-Meier plots of time to first confirmed study-emergent
primary malignancy were similar for the 2 treatment cohorts.
Cox proportional hazards modeling, adjusting for confounders
and risk factors, resulted in a hazard ratio (omalizumab vs
nonomalizumab) of 1.09 (95% CI, 0.87-1.38) for all
malignancies and 1.15 (95% CI, 0.83-1.59) for all malignancies
excluding NMSC.
Conclusion: Results from EXCELS suggest that omalizumab
therapy is not associated with an increased risk of malignancy.
(J Allergy Clin Immunol 2014;134:560-7.)
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Omalizumab (Xolair; Novartis Pharmaceuticals, Basel,
Switzerland), a humanized anti-IgE mAb, is indicated in the
United States for treatment of adults and adolescents (>_12 years of
age) with moderate-to-severe persistent allergic asthma whose
symptoms are inadequately controlled with inhaled corticoste-
roids.1 In controlled clinical studies conducted in patients receiving
maintenance therapy with inhaled corticosteroids, long-acting
b2-agonists, or both, addition of omalizumab reduced asthma exac-
erbations, decreased inhaled corticosteroid and rescue medication
use, and improved symptom control and quality of life.2-7 How-
ever, a 2003 analysis of pooled clinical trial data in 2003 showed
malignancies in 0.5% of omalizumab-treated patients compared
with 0.2% of control subjects.8 Consequently, the package insert
for omalizumab includes malignancy as a potential risk.
The Epidemiologic Study of Xolair (omalizumab): Evaluating
Clinical Effectiveness and Long-term Safety in Patients with
Moderate-to-Severe Asthma (EXCELS) was initiated as a post-
marketing commitment to the US Food and Drug Administration
to assess the long-term safety of omalizumab and provided the
opportunity to evaluate malignancy rates in clinical practice.
Interim data from EXCELS have been published previously.9-12
EXCELS was completed in April 2012, and we report the final
analysis of the incidence of malignancy.METHODS
Patients
EXCELS enrolled patients between June 2004 and November 2006.
Patients were recruited from a variety of practice settings, including managed
care organizations, community physicians’ practices, and academic centers.
Patients were eligible for inclusion if they were 12 years of age or older with
moderate-to-severe allergic physician-diagnosed asthma and had a positive
skin test result or in vitro reactivity to a perennial aeroallergen (eg, RAST).
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Clinical Effectiveness and Long-term Safety in Patients
with Moderate-to-Severe AsthmaNMSC: Nonmelanoma skin cancerPH: Proportional hazardsSAE: Serious adverse eventSEER: Surveillance Epidemiology and End ResultsPatients had to be willing to participate for the 5-year study duration. Key
exclusion criteria included the following: acute asthma exacerbation within 2
weeks before screening; acute flare of significant systemic disease (eg,
infection, hematologic, renal, hepatic, cardiovascular, or gastrointestinal
diseases) or recent hospitalization because of their disease within the previous
2 months; diagnosis of cystic fibrosis; and contraindication for omalizumab
therapy. According to the original protocol (dated December 22, 2003), prior
malignant neoplasm, a premalignant condition, or current investigation for
possible cancer diagnosis were exclusion criteria. However, the study protocol
was amended on September 23, 2005, to allow enrollment of patients with
these characteristics.Study design
EXCELS was a phase IV, prospective, observational cohort study of
omalizumab-treated and nonomalizumab-treated patients enrolled from multi-
ple US centers and followed for up to 5 years. The primary objective of the study
was to compare the long-term clinical safety profile of patients treated with
omalizumab with that of similar patients who had not been treated with
omalizumab. Study primary outcome measures included all confirmed study-
emergent primary malignancies (hereafter referred to as malignancies), all
malignancies excluding nonmelanoma skin cancer (NMSC), and incidence of
serious adverse events (SAEs; data outside the scope of the present publication).
Patients were screened consecutively as they presented at the clinic and
were prescribed treatment as clinically indicated at the treating physician’s
discretion (without randomization). Eligible patients who consented entered
study cohorts according to their use of omalizumab at enrollment. Patients
already receiving omalizumab at enrollment or initiating omalizumab within
30 days after study entry were assigned to the omalizumab cohort. Patients
were designated as ‘‘new starts’’ if they had initiated omalizumab within 7
days before or 30 days after enrollment into the omalizumab cohort to identify
subjects who had recently started treatment. The nonomalizumab cohort
enrolled patients who had not previously been treated with omalizumab and
did not initiate omalizumab within 30 days after study entry. Cohort
enrollment was in a 2:1 ratio (omalizumab/nonomalizumab), which was
maintained at the site level by the enrolling investigators; maintenance of this
ratio was approximate, depending on the types of patients presenting at the
individual sites. During the study, a patient’s ongoing treatment was
determined by the treating physician. Consequently, some patients in the
nonomalizumab cohort switched to omalizumab during the study, and some
patients in the omalizumab cohort discontinued omalizumab during the study
(see the ‘‘Patient disposition’’ section below).
After a baseline visit, study visits were scheduled every 6 months.
Nonstudy medical care visits were dictated by the patient’s requirements for
medical reasons and routine asthma care. Routine clinic visits for patients
treated with omalizumab were every 2 or 4 weeks for omalizumab injections.
The protocol was approved by a local or central institutional review board at
each study site.Assessments
Study evaluations at baseline and during the study have been described
previously.9 Briefly, baseline evaluation included detailed assessment of
asthma history, allergy and asthma medication use, and overall health. Thetreating physician determined asthma severity. All patients’ data were
collected with an electronic data-capture system.
Enrolled patients were classified into 1 of 3 baseline cancer status
categories: category A patients were cancer free, with no personal cancer his-
tory and no premalignant conditions at baseline; category B patients had no
active cancer at baseline but had a personal cancer history or precancerous
condition; and category C patients had active cancer at baseline.
A detailed cancer history was collected at the baseline visit for patients
enrolled after the protocol amendment and gathered retrospectively for pa-
tients enrolled previously; patients who could not be accurately assigned
were not categorized.Identification, authentication, and attribution of
primary malignancy events
Specific questions relating to safety, such as SAEs and malignancy events,
were queried at all study visits; malignant neoplasmswere reported as theywere
detected. Search methods to identify all reported malignancy adverse events
(AEs) included review of all events indicated by the study centers as serious or
nonseriousmalignancies, all events identified by using the standardizedMedical
Dictionary for Regulatory Activities query search for malignancy preferred
terms, and any additional events that could potentially be malignant conditions.
All potential malignancies were reviewed and adjudicated by external inde-
pendent oncologists to confirm them as true malignancies and distinguish
primary malignant conditions from metastases, progression, or recurrence of a
previously reportedmalignancy. AllmalignancyAEs reported for patients of the
omalizumab cohort were attributed to the omalizumab cohort, regardless of
whether omalizumab had been discontinued. Thus, person-time at risk for the
omalizumab cohort continued to accrue after discontinuation of omalizumab.
For patients in the nonomalizumab cohort who initiated omalizumab during the
study, only study-emergent malignancy AEs with onset dates before the patient
began omalizumab were counted as nonomalizumab malignancies, and
consistent with this accounting, person-time at risk for these malignancies
ceased to accrue at the time of switching to omalizumab. Study-emergent
malignancy events reported for patients initially assigned to the nonomalizumab
cohort with onset dates after the start of omalizumab treatment were summa-
rized separately.Statistical analysis
Analyses in this observational study focused on descriptive statistics and
estimates of treatment effects with corresponding CIs, rather than hypothesis
testing. No adjustments were made to estimates or confidence levels to
account for multiple comparisons. Statistical analyses were performed with
SAS statistical software (version 9.2; SAS Institute, Cary, NC). The primary
analysis of malignancy risk modeled the time to first confirmed study-
emergent primary malignancy by using the Cox proportional hazards (PH)
model and was based on all patients enrolled into the omalizumab and
nonomalizumab cohorts. The time to first primary malignancy was defined as
the number of months from day 0 (defined as the date of the study visit at
which a patient’s final baseline evaluations were completed) to the date of
onset of symptoms for the first confirmed primary malignancy (or next
primary malignancy in patients who entered the study with a pre-existing
malignancy). If a patient died, was lost to follow-up, discontinued from the
study, initiated omalizumab after being enrolled in the nonomalizumab cohort,
or completed the study before experiencing a malignancy, then that patient’s
follow-up time was censored at the earliest of these dates. Per the prespecified
analysis, the Cox PH model was stratified by baseline cancer status (category
A, B, or C) and adjusted for baseline risk covariates: treatment cohort
(omalizumab or nonomalizumab), age, race (white or nonwhite), sex, smoking
history (current, former, or never), family history of cancer (yes, no, or
unknown), investigator-assessed asthma severity (moderate or severe), and
body mass index at baseline (<30 kg/m2 or >_30 kg/m2). The time to first
confirmed study-emergent primarymalignancy was also summarized by treat-
ment cohort by using Kaplan-Meier estimates.
Overall incidence rates for malignancies (and malignancies excluding
NMSC) per 1000 person-years of observation time were computed (from
FIG 1. Patient disposition. *Patients with missing omalizumab treatment information at baseline or who
were previously treated with omalizumab but were not receiving omalizumab at the time of enrollment.
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and reported with exact 95% CIs. The ratios and differences in malignancy
incidence rates between the omalizumab and nonomalizumab cohorts were
computed and reported with 95% CIs calculated by using a bias-corrected
bootstrap procedure.
Observed rates for individual cancer types (except NMSC, which is not
captured in the Surveillance Epidemiology and End Results [SEER] database)
were compared with the number of cases that would be expected if the age-
and sex-specific incidence rates recorded in the SEER database were applied
to the age and sex distribution in EXCELS. Standardized morbidity ratios
were calculated.13 Because of small stratum sizes, separate analyses of spe-
cific age subgroups were not performed (eg, pediatric subjects).
Sensitivity analyses. Potential sources of bias in the malignancy
analysis included recall bias, malignancy detection bias arising from the open-
label nature of the study and the more frequent medical office visits in the
omalizumab group, selection/survivor bias arising from inclusion of patients
receiving omalizumab before enrollment, and the confounding of treatment
comparisons caused by cohort differences in baseline characteristics. These
potential biases were evaluated by using various sensitivity and exploratory
analyses. Propensity score estimates were calculated for patients by using
logistic regression to model the probability of receiving omalizumab as a
function of potentially confounding baselinevariables in an exploratory analysis
of malignancy risk to reduce potential confounding. Time to first study-
emergent confirmed primary malignancy was modeled by using the Cox PH
model, including treatment cohort (omalizumab treated or nonomalizumab
treated) and the propensity score as covariates in the model. Omalizumab-
treated patients were seen every 2 or 4 weeks (for drug administration) rather
than every 6 months for the nonomalizumab-treated patients. Thus, patients
receiving omalizumab might have more consistently reported malignancy
events because they had more frequent medical office visits. Furthermore,
patients and investigators might have been more vigilant in screening for and
identifying cancer events in patients receiving omalizumab because they had
more frequent visits. The potential for recall biaswas evaluated for skin cancers,
asthma exacerbations, and selected other events by examining the distribution of
onset dates relative to reporting dates. The frequencies of various cancer-
screening procedures were summarized by treatment cohort over time to
evaluate the potential for malignancy detection bias. Furthermore, inanticipation of the potential for detection bias in skin cancers, the incidence
and risk of all malignancies excluding NMSC were analyzed in a parallel
fashion to the incidence and risk of all malignancies (including NMSC; primary
outcome). The incidence of malignancy in patients in the omalizumab cohort
who were considered omalizumab naive (ie, ‘‘new starts’’) was compared with
that of patients in the nonomalizumab cohort to address the potential for
selection/survivor bias. Censoring patterns within the 2 treatment cohorts were
examined to evaluate the possibility of informative censoring (ie, biased
censoring related to the risk of malignancy or SAEs). Given the long duration of
the study, it was anticipated that time to malignancy outcomes would be
censored in a sizeable number of patients because of premature discontinuation
from the study or change in asthma treatment before completing the 5-year
follow-up. The potential for informative censoring was therefore evaluated by
monitoring the frequency and reasons for study discontinuation and censoring.
Subgroup and exploratory analyses. A subgroup analysis
of malignancies (all malignancies and excluding NMSC) according to cancer
status at baseline was prespecified in the study protocol, as was an exploratory
analysis conducted for the omalizumab-treated cohort based on total time on
omalizumab, including exposure before and during the study.
RESULTS
Patient enrollment
A total of 7857 patients were enrolled in the study from 445 sites
(omalizumab cohort, n5 5007; nonomalizumab cohort, n5 2829;
initially enrolled but ineligible, n5 21; Fig 1). The small group of
initially enrolled patients (n 5 21) did not meet the eligibility
criteria for enrollment into EXCELS because they had missing
omalizumab treatment information at baseline or were previously
treated with omalizumab but were not receiving omalizumab at
the time of enrollment. The baseline data for these patients were
summarized separately as the not eligible group (data not shown),
and these patients were not included in the analyses of safety out-
comes. A total of 4398 (56.0%) patients were enrolled before and
3459 (44.0%) were enrolled after the protocol amendment, allow-
ing inclusion of patients at risk of/with a history of malignancy.
TABLE I. Patients’ baseline characteristics
Omalizumab
cohort (n 5 5007)
Nonomalizumab
cohort (n 5 2829)
Mean (SD) age (y) 44 (17) 46 (17)
Female sex, no. (%) 3199 (63.9) 1880 (66.5)
Mean (SD) BMI (kg/m2) 31 (11.9) 31 (12.9)
Race: white, no. (%) 3949 (78.9) 2322 (82.2)
Smoking history, no. (%)
Current 245 (4.9) 159 (5.6)
Former 1477 (29.5) 826 (29.2)
Baseline cancer status, no. (%)
Cancer-free and no previous
cancer history (category A)
4511 (90.1) 2521 (89.1)
No active cancer but cancer 432 (8.6) 276 (9.8)
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More than half of the enrolled population (55.9%) completed the
study (Fig 1). In the omalizumab cohort 1622 (32.4%) patients
stopped omalizumab treatment for at least 6 months during the
study: primary reasons included therapy expense/out-of-pocket
costs (10.5%), lack of response (5.5%), and other reasons
(10.2%), including issues relating to insurance coverage, physi-
cian’s recommendation, and/or patient’s decision to discontinue.
In the nonomalizumab cohort 275 (9.7%) patients started omalizu-
mab treatment during the study. Among all patients in the nonoma-
lizumab cohort, the most frequent reasons for starting omalizumab
therapy were as follows: unresponsive to current therapy (6.2%)
and interest in reducing other asthma medications (0.8%).history (category B)
Active cancer (category C) 35 (0.7) 19 (0.7)
Unclassified* 29 (0.6) 13 (0.5)
Physician-assessed asthma
severity, no. (%)
Moderate 2519 (50.4) 2185 (77.4)
Severe 2482 (49.6) 637 (22.6)
Baseline IgE level (IU/mL),
median
202.0 108.0
Intubation caused by asthma,§
no. (%)
419 (8.4) 128 (4.5)
Daily use of asthma controller
medications,k no. (%)
4172 (83.5) 2066 (73.3)
Daily use of asthma quick-relief
medications,k no. (%)
1120 (22.4) 420 (14.9)
Note: The first protocol amendment removed exclusion of patients with active cancer
or cancer history.
BMI, Body mass index.
*Missing data for 1 or more variables.
Omalizumab, n 5 5001; nonomalizumab, n 5 2822.
For omalizumab-treated patients: level reported at the time of initial omalizumab
dosing, n 5 4998; for nonomalizumab-treated patients: level reported at the time of
the baseline visit, n 5 2782.
§Omalizumab, n 5 4993; nonomalizumab, n 5 2825.
kOmalizumab, n 5 4999; nonomalizumab, n 5 2818.Omalizumab treatment and follow-up
In the final data set, follow-up was 18,426 person-years in the
omalizumab cohort and 10,844 person-years in the nonomalizu-
mab cohort (approximately 9,963 person-years before omalizumab
exposure and approximately 882 person-years after omalizumab
initiation). Median follow-up was approximately 5 years for both
cohorts. The mean prestudy duration of omalizumab treatment for
the 5,007 patients in the omalizumab cohort was 7.9 months (SD,
7.6 months). The majority of these patients (4,418 [88.3%]) were
considered established users of omalizumab at the time of study
enrollment; 587 (11.7%) of the omalizumab cohort patients were
classified as ‘‘new starts’’ and represent an omalizumab-naive
population. The median duration of on-study omalizumab treat-
ment for the omalizumab cohort was 36.6 months (range, 0-73).
The mean total treatment duration, including treatment before
study enrollment and on study, was 43.1months (SD, 24.8months).
Approximately 70%of patients in this cohort received omalizumab
for 2 or more years. The median duration of omalizumab treatment
for the 275 patients in the nonomalizumab cohort who started
omalizumab during the study was 24.4 months (range, 0-60
months).Patients’ characteristics at baseline
Patients were predominantly white, female, nonsmoking, and
cancer free with no previous cancer history (Table I). However,
the omalizumab cohort had higher baseline IgE levels, and a
higher proportion of patients were classified as having severe
asthma, higher use of daily asthma controller and quick-relief
medications, and a higher likelihood of having been intubated
compared with the nonomalizumab cohort.Confirmed primary study-emergent malignancy
AEs
A total of 625 potential malignancy events were identified. Of
these, 38 events were not submitted for external adjudication
based on an internal clinical review, which determined that 28
represented procedures that are often performed to diagnose or
treat a malignant condition (eg, hysterectomy) but were not
malignancies and 10 represented an obvious benign condition (eg,
uterine fibroid) or worsening/recurrence of a previously reported
malignancy. Of the 587 events submitted for external adjudica-
tion, 80 events were not assessed to be primary malignancies, and
10 events were excluded because they were not study emergent (7
events) or were reported for patients in the not eligible group (3events). The remaining 497 malignancy AEs in 354 patients were
adjudicated as confirmed primary study-emergent malignancies
(Fig 2). These events occurred in 220 patients (295 malignancies)
in the omalizumab cohort and 126 patients (190 malignancies) in
the nonomalizumab cohort. A further 12 malignancies occurred
in 8 patients in the nonomalizumab cohort after omalizumab
treatment was initiated. The most common malignancy AEs re-
ported in each cohort were skin cancer (nonmelanoma), followed
by breast cancer, prostate cancer, colorectal cancer, melanoma,
and lung cancer. Fewmeaningful differences were noted between
observed frequencies of individual cancer types and expected fre-
quencies based on SEER data,13 especially when the precision of
each rate was taken into account (see Table E1 in this article’s On-
line Repository at www.jacionline.org).Crude rates of confirmed study-emergent primary
malignancies
Crude rates of malignancies (per 1000 person-years) were
computed for each cohort for all malignancies and all malignancies
excludingNMSC (Table II). Crude rates ofmalignancies were 16.0
and 19.1 per 1000 patient-years in the omalizumab and
FIG 2. Assessment of potential malignancy events. *Events identified by using the standardized Medical
Dictionary for Regulatory Activities query (SMQ). Data are for patients in the nonomalizumab cohort before
initiation of omalizumab treatment. Patients with missing omalizumab treatment information at baseline
or who were previously treated with omalizumab but were not receiving omalizumab at the time of
enrollment.
TABLE II. Study-emergent primary malignancy AE crude rates in enrolled patients
Omalizumab
cohort (n 5 5007)
Nonomalizumab*
cohort (n 5 2829)
Crude differences in
rates (95% CI) Crude ratio of rates
Person-years at risk for any malignancy 18,425.5 9,962.6
No. of malignancy events (any type) 295 190
Malignancy rate (any type [95% CI]) 16.0 (14.2 to 17.9) 19.1 (16.5 to 22.0) 23.06 (29.19 to 2.03) 0.84 (0.62 to 1.13)
No. of malignancies (excluding NMSC events) 114 63
Malignancy rate (excluding NMSC [95% CI]) 6.2 (5.1 to 7.4) 6.3 (4.9 to 8.1) 20.14 (22.23 to 1.80) 0.98 (0.71 to 1.36)
*All nonomalizumab-treated patients before any treatment with omalizumab.
Allows for multiple events per patient.
All rates and their differences are expressed as per 1000 patient-years.
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excluding NMSC were 6.2 and 6.3 per 1000 person-years in the
omalizumab and nonomalizumab cohorts, respectively.Time to first study-emergent confirmed primary
malignancy
Kaplan-Meier plots of time to first confirmed study-emergent
primary malignancy (Fig 3) and primary malignancy excluding
NMSC (Fig 4) appeared similar for the omalizumab and nonoma-
lizumab cohorts. Results of the analyses of time to first study-
emergent confirmed primary malignancy based on the Cox PH
model stratified by baseline cancer status and including treatment
cohort and other cancer risk factors as covariates in the model are
summarized in Table III. The hazard ratio comparing the risks of
malignancy for the omalizumab cohort versus the nonomalizu-
mab cohort was 1.09 (95% CI, 0.87-1.38). Similar results were
obtained when time to first study-emergent confirmed primary
malignancy (excluding NMSC) was modeled (1.15; 95% CI,
0.83-1.59).Nonmalignant SAEs
Overall, 1263 (25.2%) patients in the omalizumab cohort and
571 (20.2%) patients in the nonomalizumab cohort reported
having 1 or more study-emergent SAE(s) (excluding malignancy
AEs). The system organ classes most commonly affected were as
follows: respiratory, thoracic, and mediastinal disorders; infec-
tions and infestations; and cardiac disorders. The frequency of
study-emergent SAEs by system organ class occurring in patients
at a frequency of 1% or greater in either cohort is provided in
Fig E1 in this article’s Online Repository at www.jacionline.org.Exploratory and subgroup analyses
Propensity scores were used to reduce potential confounding
by adjusting for the probability of receiving omalizumab. The
hazard ratios corresponding to the treatment cohort covariate
(omalizumab vs nonomalizumab) from Cox PH models with
propensity score quintiles as covariates were consistent with the
results from the primary analyses (see Table E2 in this article’s
Online Repository at www.jacionline.org). A Cox PH model
FIG 3. Kaplan-Meier plots of time to first confirmed study-emergent primary malignancy (all primary
malignancies). The vertical axis is magnified to enhance visualization of curves.
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very similar results (data not shown).
In general, the omalizumab and nonomalizumab cohorts
reported similar cancer-screening rates across study visits. The
crude rates of malignancies (per 1000 person-years) for the
omalizumab ‘‘new starts’’ were 16.3 (95% CI, 11.1-23.0) for all
malignancies and 6.6 (95% CI, 3.5-11.3) for all malignancies
excluding NMSC and are consistent with the crude rates
calculated for the overall omalizumab cohort. Proportions of
patients with censored observations, distribution of reasons for
censoring, and mean time to censoring were similar between
cohorts.
Among patients with no active cancer at baseline but with a
personal cancer history or premalignant condition (category B,
n 5 708), crude malignancy rates were 55.4 (95% CI, 44.92-
67.58) and 63.2 (95% CI, 49.2-80.03) per 1000 patient-years in
the omalizumab and nonomalizumab cohorts, respectively.
Patients with active cancer at baseline (category C, n 5 54) had
crude malignancy rates of 89.7 (95%CI, 46.33-156.61) and 206.7
(95% CI, 115.67-340.88) per 1000 patient-years in the omalizu-
mab and nonomalizumab cohorts, respectively. The majority of
patients in both cohorts were cancer free at baseline (category A,
n 5 7032) and had crude malignancy rates of 11.23 (95% CI,
9.67-12.97) and 12.07 (95% CI, 9.88-14.60) in the omalizumab
and nonomalizumab cohorts, respectively.
Kaplan-Meier estimates of time to first malignancy were
similar for patients in the omalizumab cohort stratified by
omalizumab exposure before enrollment: omalizumab ‘‘new
starts’’ (n 5 587); greater than 7 days to 1 year of omalizumab
before enrollment (n 5 3220); and greater than 1 year of
omalizumab before enrollment (n 5 1199; see Fig E2 in this ar-
ticle’s Online Repository at www.jacionline.org).DISCUSSION
The clinical benefit of omalizumab has been established in
several large clinical trials.2-6,14,15 However, concern regarding a
potential association with malignancy risk has led to a need to
evaluate further the long-term safety of omalizumab. EXCELS
is the first study to evaluate the long-term safety of omalizumab
in a large population of patients with moderate-to-severe allergic
asthma in a real-world setting.
EXCELS had a median follow-up of approximately 5 years for
both the omalizumab and nonomalizumab cohorts and included
patients at high risk of cancers (smokers and family history of
cancer) and patients with a history of malignancy. Analyses of
time to first primary malignancy adjusted for potential con-
founders also demonstrated similar risk between the 2 cohorts.
These results suggest that omalizumab is not associated with an
increased risk of malignancy, a conclusion also supported by the
results of the sensitivity analyses. In addition, although patient
numbers in subgroup analyses of subjects with a personal history
of cancer/premalignant condition and patients with active cancer
at baseline were small, the results suggest that omalizumab is not
associated with a risk of malignancy progression. An exploratory
analysis of cumulative omalizumab exposure on malignancy risk
showed no meaningfully increased risk of malignancy.
Reported malignancies were predominantly solid tumors, with
no unexpected histologic patterns observed. The most common
cancers in both cohorts were skin, breast, and prostate cancer. On
the basis of SEER data, both the overall frequency and the
frequency of individual cancer types observed in EXCELS are
consistent with expectations for the general population. The
results of EXCELS are also consistent with a recent analysis of
pooled data from 67 phase I to phase IV clinical trials that
reported no association between omalizumab and malignancy
FIG 4. Kaplan-Meier plots of time to first confirmed study-emergent primary malignancy (all primary
malignancies excluding NMSC). The vertical axis is magnified to enhance visualization of curves.
TABLE III. Cox PH model* of time to first confirmed study-
emergent primary malignancy
Parameter
estimate SE
HR
(95% CI)
Any malignancy
Treatment (omalizumab vs
nonomalizumab)
0.088 0.118 1.09 (0.87-1.38)
Malignancies excluding NMSC
Treatment (omalizumab vs
nonomalizumab)
0.137 0.168 1.15 (0.83-1.59)
HR, Hazard ratio.
*Adjusted for age, race, sex, smoking history, family cancer history, asthma severity,
and body mass index stratified by baseline cancer status.
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the earlier 2003 pooled analysis.8,16 However, most of the studies
included in this pooled analysis had a short duration of follow-up,
and the effect of longer-term omalizumab therapy could not be
fully assessed.16 Although EXCELS was large and patients
were followed for up to 5 years, the study size and follow-up
time were insufficient to detect a meaningful increase in rates
for individual cancer types (as opposed to the overall malignancy
rates this study was designed to detect). In addition, follow-up
was insufficient to assess slow-growing malignancies associated
with a longer latency period.
Potential confounding in EXCELS was addressed by Cox PH
analyses stratified by baseline cancer status and adjusted for
patients’ characteristics. These analyses provided similar results
to the unadjusted analysis, implying a lack of any important
confounding. Multiple exploratory and sensitivity analysesevaluated potential sources of bias in the analysis of malignancy.
The consistency of malignancy rates between omalizumab ‘‘new
starts’’ and the nonomalizumab cohort in the primary analysis
(rate ratio, 0.85; 95% CI, 0.49-1.36) provides evidence against a
selection bias caused by the inclusion of patients started on
omalizumab before enrollment (‘‘established users’’). The
comparability of the cohorts with respect to the on-study
surveillance for malignancy, along with the similarity between
cohorts with respect to malignancy rates (including and excluding
NMSC), provides reassurance against meaningful detection bias.
In addition, similarities between cohorts regarding proportions of
patients with censored observations, distribution of reasons for
censoring, and the mean time to censoring provided no clear
indication of informative censoring.
In conclusion, the results from EXCELS suggest that omali-
zumab is not associated with an increased risk of malignancy. The
results from multiple exploratory and sensitivity analyses,
expected rates in the general population, and limited evidence
of biologic plausibility17-22 support this conclusion.
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Clinical implications: This study reports prospective clinical
practice data indicating that omalizumab therapy is not associ-
ated with an increased risk of malignancy.
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FIG E1. Frequency of study-emergent SAEs by system organ class occurring in patients at a frequency of 1%
or greater in the omalizumab and nonomalizumab cohorts.
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FIG E2. Kaplan-Meier estimates of time to first confirmed study-emergent primary malignancy AE by
duration of omalizumab exposure before enrollment in all enrolled patients in the omalizumab cohort. The
vertical axis is magnified to enhance visualization of the curves.
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TABLE E1. Standardized morbidity ratios in reference to the SEER database* for selected malignancies with an overall frequency
of greater than 7
Tumor type
Omalizumab cohort (n 5 5007) Nonomalizumab cohort (n 5 2829)
No. of malignancy events No. of malignancy events
Observed Expected SMR 95% CI Observed Expected SMR 95% CI
All malignancies (excluding NMSC) 114 125.4 0.91 0.75-1.09 63 76.8 0.82 0.64-1.04
Breast cancer 29 25.4 1.14 0.78-1.62 13 15.5 0.84 0.47-1.39
Prostate cancer 17 16.0 1.06 0.64-1.66 5 9.2 0.54 0.21-1.19
Colorectal cancer 14 11.5 1.21 0.70-1.98 3 7.2 0.41 0.11-1.11
Melanoma 8 5.4 1.47 0.69-2.78 5 3.2 1.58 0.60-3.46
Lung cancer 6 16.1 0.37 0.15-0.77 7 10.5 0.66 0.30-1.31
Thyroid cancer 7 3.7 1.91 0.85-3.76 1 2.0 0.49 0.04-2.30
SMR, Standardized morbidity ratio.
*SEER Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data 1 Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub, Vintage
2009 Pops (2000–2009) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance
Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission.
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TABLE E2. Cox PH model of time to first confirmed study-
emergent primary malignancy adjusted for propensity score
quintile and stratified by baseline cancer status
Parameter
estimate SE HR (95% CI)
Any malignancy
Treatment (omalizumab vs
nonomalizumab)
0.132 0.128 1.14 (0.89-1.47)
Malignancies excluding NMSC
Treatment (omalizumab vs
nonomalizumab)
0.261 0.185 1.30 (0.90-1.87)
HR, Hazard ratio.
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